TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11786587
Drug: Oral megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral megestrol acetate 800 mg/d liquid suspension plus placebo
Study: 11786587
Drug: Oral dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dronabinol 2.5 mg twice a day plus placebo
Study: 11786587
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (dronabinol and megestrol acetate)
Study: 11786587
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Anorexia/Cachexia Therapy questionnaire
Study: 7926080
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg orally twice daily for 4 months)
Study: 27041263
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil (prophylactic administration)
Study: 21374895
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with high disability and limitations in daily living
Study: 2483979
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo treatment
Study: 31447131
Drug: Niacin/Laropiprant (2000/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin/Laropiprant (2000/40 mg/d)
Study: 28891419
Drug: Listening to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listening to Holy Qur'an recitation in combination with endurance‐resistance training (n = 28)
Study: 26568566
Drug: Intermittent ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent ART (I-ART) for 2 years, consisting of 6 month periods on once-daily boosted-PI-based ART, alternating with 6 month periods without ART.
Study: 11486703
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G‐CSF)
Study: 19237716
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d)
Study: 11560871
Drug: Diltiazem (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (200 mg)
Study: 9934573
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of lidocaine hydrochloride
Study: 9934573
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of saline
Study: 7946688
Drug: iohexol 350
Normalized name: iohexol 350 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 350 mg I/ml with NaCl 28 mmol/l
Study: 27031165
Drug: Effective microorganism-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective microorganism-X (EM-X) supplementation (70 ml·day(‐1))
Study: 20078917
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg, 3 times daily as needed for up to 7 days
Study: 20078917
Drug: Cyclobenzaprine 5
Normalized name: cyclobenzaprine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine 5 mg, 3 times daily as needed for up to 7 days
Study: 20078917
Drug: Both ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both ibuprofen and cyclobenzaprine, 3 times daily as needed for up to 7 days
Study: 18616688
Drug: Trazodone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50 to 150 mg at bedtime) for 12 weeks
Study: 16911750
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment (10 treatments, on business days)
Study: 16911750
Drug: Spaced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced treatment (five treatments, on spaced business days)
Study: 2126741
Drug: Hydrophilic NTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic NTG oral spray (0.8 mg)
Study: 2126741
Drug: Lipophilic NTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipophilic NTG oral spray (0.8 mg)
Study: 22470104
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine lozenge (NL)
Study: 28060837
Drug: CSL‐111 (reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL‐111 (reconstituted HDL) 40 mg/kg, administered as 4 weekly intravenous infusions
Study: 19586828
Drug: 1 mg/mL
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL morphine and 10 microg/mL nalbuphine (1:100)
Study: 19586828
Drug: 1 mg/mL
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL morphine
Study: 11210399
Drug: Carbatrol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbatrol (200 mg) with a high-fat meal
Study: 11210399
Drug: Carbatrol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbatrol (200 mg) fasted
Study: 11210399
Drug: Carbatrol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbatrol (200 mg) sprinkled over applesauce (but otherwise fasted)
Study: 7542052
Drug: Fluvoxamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (200 mg/day for 4 weeks or individualized dosing for 6 weeks)
Study: 356970
Drug: Chemoimmunotherapy (DTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5; methanol extracted residue of bacillus Calmette-Guérin 0.5 mg intradermally every 5 weeks)
Study: 356970
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5)
Study: 20445533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benazepril and valsartan
Study: 20445533
Drug: Control (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single-agent treatment with benazepril or valsartan)
Study: 18349171
Drug: Beta-blockers (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (specific mention of metoprolol and other beta-blockers)
Study: 8706442
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol in combination with laminaria or tamoxifen
Study: 3865687
Drug: PGE2 (100-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 (100-500 micrograms ml-1)
Study: 3865687
Drug: PGF2 alpha
Normalized name: Prostaglandin PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2 alpha (0.1-100 micrograms ml-1)
Study: 3865687
Drug: Acetylcholine (0.1-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (0.1-50 mg ml-1)
Study: 31492716
Drug: IV glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV glucose infusion (10% glucose at 410 mL/h)
Study: 31492716
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose supplementation (2% concentration soft drink)
Study: 26768929
Drug: 3mg/kg 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg 0.5% prilocaine + 2 mL (100mg) tramadol
Study: 26768929
Drug: 3mg/kg 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg 0.5% prilocaine + 2 mL (8 mg) lornoxicam
Study: 24657033
Drug: N-acetylcystein 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcystein 150 mg/kg followed by 50 mg/kg for 6 hours in 0.9% saline
Study: 18064525
Drug: 2 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l/min oxygen via nasal prongs
Study: 18064525
Drug: 6 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 l/min oxygen through a rebreathing face mask
Study: 11835022
Drug: Oral GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GP IIb/IIIa inhibitors
Study: 14519089
Drug: Intravenous GP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GP IIb/IIIa receptor blockers
Study: 6743481
Drug: Cimetidine 600
Normalized name: cimetidine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 600 mg twice daily
Study: 24717711
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fluoride therapy)
Study: 17454195
Drug: Chemotherapy (CHT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHT) without GnRH‐a
Study: 2057991
Drug: Computer program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer program predicting warfarin dosage adjustments
Study: 29304199
Drug: monovalent high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: monovalent high‐dose type 2‐specific IPV (mIPV2HD)
Study: 19058332
Drug: Antioxidant enteral
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant enteral supplement
Study: 16837793
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy at the dose of 0.23 mg/kg/week s.c.
Study: 12802751
Drug: Oral pleconaril
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pleconaril
Study: 9554153
Drug: Breast-feeding (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-feeding (at least once daily)
Study: 1527286
Drug: Anistreplase (APSAC)
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase (APSAC) 30 U/2 to 5 min with aspirin (160 mg/day) and intravenous heparin
Study: 1527286
Drug: Alteplase (rt-PA)
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase (rt-PA) 100 mg/3 h with aspirin (160 mg/day) and intravenous heparin
Study: 31948255
Drug: Physiotherapy intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy intervention (daily exercises aimed at the foot arch)
Study: 18796517
Drug: Genistein aglycone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein aglycone (54 mg daily)
Study: 18214021
Drug: High-iron rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-iron rice (3.21 mg/kg Fe)
Study: 18214021
Drug: Control rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control rice (0.57 mg/kg Fe)
Study: 2958282
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (20 mg/2 ml)
Study: 2958282
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (500 micrograms/2 ml)
Study: 2958282
Drug: Verapamil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (5 mg/2 ml)
Study: 2958282
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg in 4 ml) after placebo (4 ml saline)
Study: 2665559
Drug: 0.32 g
Normalized name: ZINC OXIDE 0.32 g in 4 g TOPICAL STICK [eos Natural SPF 15 Lip Balm Pineapple Coconut]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32 g alcohol/kg body weight
Study: 2665559
Drug: 0.65 g
Normalized name: Tumil-K 2 MEQ/0.65 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g alcohol/kg body weight
Study: 2665559
Drug: 0.81 g
Normalized name: TITANIUM DIOXIDE 0.81 g in 45 g CUTANEOUS CREAM [THE SKIN EXTRA BB SPF20 PA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.81 g alcohol/kg body weight
Study: 779949
Drug: 5-FU 400
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400 mg/m2 weekly intravenously
Study: 779949
Drug: 5-FU 400
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400 mg/m2 i.v. weekly plus methyl-CCNU 175 mg/m2 orally every 6 weeks
Study: 30402705
Drug: Reduced bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced bowel preparation (r‐CTC)
Study: 30402705
Drug: Full bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full bowel preparation (f‐CTC)
Study: 29141858
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg daily subcutaneous injections for 12 weeks
Study: 29141858
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg daily subcutaneous injections for 2 weeks
Study: 23940237
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) 5 ppm for 7 to 21 days
Study: 18041047
Drug: Drug therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapies for schizophrenic patients
Study: 29137502
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution applied to umbilical cord stumps
Study: 24270900
Drug: parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib sodium 40 mg (Group P, n=40)
Study: 24270900
Drug: tramadol 2
Normalized name: traMADol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol 2 mg/kg (Group T, n=40)
Study: 12572527
Drug: Fusafungine nasal
Normalized name: fusafungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusafungine nasal spray
Study: 9459381
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g psyllium three times daily
Study: 11114960
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg day-1)
Study: 12534449
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg day-1)
Study: 27136960
Drug: Split-dose polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose polyethylene glycol (PEG)
Study: 26281972
Drug: GLAR +
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLAR + metformin
Study: 26281972
Drug: 3OAD (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3OAD (metformin or glyburide)
Study: 18612703
Drug: Postoperative combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative combined modality adjuvant therapy (chemotherapy, chemoradiation, or both); specific dosages and durations not mentioned.
Study: 18612703
Drug: Adjuvant therapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy; specific type not mentioned.
Study: 15773068
Drug: Standard pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmaceutical grade placebo
Study: 10086330
Drug: Daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of 9 or 12 x 10(6) IL‐2 units/m2
Study: 10086330
Drug: Daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of 3 or 6 10(6) IL‐2 units/m2
Study: 7139063
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation
Study: 7139063
Drug: Three 25
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 25 mg conventional doses given at 4‐h intervals (control)
Study: 7139063
Drug: Single 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 75 mg dose of conventional capsules (control)
Study: 7139063
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose (control)
Study: 31952174
Drug: CrM-HMB (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrM-HMB (0.04 g/kg/day of CrM plus 3 g/day of HMB)
Study: 20084326
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (10 mg patch)
Study: 17027104
Drug: NO-releasing aspirin
Normalized name: aspirin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO-releasing aspirin (NORA)
Study: 15478208
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil spray or gargle formulation
Study: 11682284
Drug: Chronobiological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronobiological interventions related to reproductive hormones (specific details not provided)
Study: 10211010
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg kg‐1 as drops
Study: 10211010
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg kg‐1 from an intranasal spray device
Study: 10211010
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (both methods)
Study: 8165823
Drug: Fenoterol (F)
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (F) administered intravenously (i.v.)
Study: 8165823
Drug: Fenoterol (F)
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (F) administered orally (p.o.)
Study: 2893084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum CA‐125 measurement with ultrasound
Study: 2893084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vaginal examination with ultrasound
Study: 2893084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum CA‐125 measurement with vaginal examination
Study: 2893084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three tests (serum CA‐125 measurement, vaginal examination, ultrasound)
Study: 29501386
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication (olanzapine, clozapine, quetiapine)
Study: 28463833
Drug: 10 mg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/h clazosentan
Study: 21477171
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of caesarean and spontaneous vaginal births
Study: 12433231
Drug: Modafinil (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (three 100 mg doses per day)
Study: 1888693
Drug: Diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 300 mg once daily for 3 weeks
Study: 22151478
Drug: Abstinence-contingent recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-contingent recovery housing with reinforcement-based treatment (RH + RBT)
Study: 16389162
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin + Pio (30 mg daily)
Study: 16389162
Drug: Sulfonylurea and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea and Metformin (SU+M)
Study: 11077389
Drug: Penicillin (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (28 capsules, 500 mg each, taken every 6 hours for 7 days)
Study: 8724325
Drug: Adjunctive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment with lithium or carbamazepine
Study: 8724325
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of neuroleptics
Study: 31013372
Drug: Oral Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Immunotherapy (OIT) for peanut allergy over 2 years
Study: 30524424
Drug: Oral Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Immunotherapy (OIT) for peanut allergy
Study: 30209017
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ambrisentan 10 mg plus tadalafil 40 mg)
Study: 30209017
Drug: Monotherapy (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (either ambrisentan or tadalafil plus placebo)
Study: 22525081
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine formulation (31.5 mg) administered intranasally
Study: 22525081
Drug: Nasal inhalation
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal inhalation (gentle or vigorous sniff)
Study: 22525081
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray pump delivery device
Study: 22525081
Drug: Gentle inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentle inhalation
Study: 16000624
Drug: Propranolol (beta‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta‐adrenoceptor antagonist)
Study: 16000624
Drug: Reboxetine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (selective norepinephrine reuptake inhibitor)
Study: 11916759
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (1500 retinol equivalents or 5000 IU) and Zinc (15 mg) supplementation daily for 6 months
Study: 7564449
Drug: Warm antegrade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm antegrade delivery of cardioplegic solution (N = 25)
Study: 7564449
Drug: Warm retrograde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm retrograde delivery of cardioplegic solution (N = 25)